Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9209 USD | -0.38% | -9.28% | -33.91% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.91% | 140M | |
+9.58% | 114B | |
+11.56% | 104B | |
-14.01% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.00% | 17.89B | |
+7.64% | 14.28B | |
+36.07% | 12.55B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Seres Therapeutics Signs New $250 Million Debt Facility With Oaktree Capital Management